Form 4: Avalo Therapeutics CFO Granted Stock Options

Avalo Therapeutics' Chief Financial Officer, Christopher Ryan Sullivan, was granted 163,000 stock options on January 28, 2025.

Summary

• Christopher Ryan Sullivan, the Chief Financial Officer of Avalo Therapeutics, Inc., was granted 163,000 stock options on January 28, 2025.
• The options have an exercise price of $8.04 per share.
• The options vest 25% on January 28, 2026, and the remaining 75% vest in equal monthly installments over the following three years, contingent on continued service.
• The options expire on January 28, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no indications of negative sentiment.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Risks

• The value of the stock options is dependent on the future performance of Avalo Therapeutics' stock price.
• If the CFO leaves the company before the options fully vest, they may forfeit some or all of the options.

Future Outlook

The stock options will vest over the next four years, subject to the CFO's continued employment.

Industry Context

Granting stock options to executives is a common practice in the biotechnology industry to incentivize performance and align management's interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in publicly traded companies, particularly in the biotech sector.
• Vesting schedules, such as the one described, are also common to ensure long-term commitment from executives.
• The specific number of options and exercise price would be compared to similar roles at comparable companies to assess if the compensation is in line with industry standards.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to improve company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, CFO, Avalo Therapeutics, equity, vesting